Thelansis

  Mantle cell lymphoma (MCL) is a mature B-cell subtype of Non-Hodgkin lymphoma (NHL), characterized by translocation, primarily caused by an excessive expression of Cyclin D1. However, with the progress in our knowledge of the causes of MCL and available treatments for MCL, this cancer is still incurable. Poor prognostic indicators, such as age, male gender, rapid disease progression, significant nodal involvement, elevated serum lactate dehydrogenase level, increased expression of Ki-67, and TP53 mutation, are associated with an unfavorable outcome. The symptoms of MCL are similar to NHL, including lymphadenopathy, lymphocytosis, splenic enlargement, growth in Waldeyer's ring and tonsils, lymphomatous polyposis, and bone marrow infiltration. Interestingly, some patients may remain asymptomatic despite lymphocytosis. MCL can affect various extranodal sites, including the kidneys, soft tissues, skin, and the central nervous system (CNS). Non-nodal leukemic MCL often presents as a...